MedPage Today: Combination treatment promising for certain leukemia patients

UC expert comments on new study

A combination of low-intensity chemotherapy and an antibody-drug conjugate drug showed promise in a phase 2 trial for older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukemia (ALL).

MedPage Today highlighted the study, and patients in the study had a "significant improvement" in their five-year progression-free survival compared to historical data for this patient set, according to the study's authors.

Emily Curran, MD, medical director of the University of Cincinnati Cancer Center Clinical Trials Office and assistant professor of Internal Medicine in UC's College of Medicine, authored a corresponding commentary on the study, published in The Lancet Hematology.

The study "provides impressive results, with survival outcomes that far exceed historic survival data in older adults with acute lymphocytic leukemia," Curran wrote in the commentary.

Read the MedPage Today article.

Featured photo at top: Dr. Emily Curran examines specimens using a microscope in her lab. Photo/Colleen Kelley/UC Marketing + Brand.

Related Stories

1

Protecting the brain with chemistry

April 24, 2026

UC chemistry student Carter St. Clair will pursue his interest in computational chemistry through a new fellowship at the Air Force Research Laboratory. His topic: new applications in AI in human health.

2

A family tradition continues at UC College of Nursing

April 24, 2026

When Ashley Enginger walks across the stage at this spring’s commencement ceremony, she will leave behind a UC College of Nursing that her family is far from finished with. Her sister Sarah is already two years in, and their youngest sister Lauren is set to arrive in the fall.